33 results about "Gamma hydroxybutyrate" patented technology

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

The present invention provides a solid immediate release dosage form adapted for oral administration of GHB. The solid immediate release dosage form includes an immediate release formulation comprising a relatively high weight-percentage of GHB with a bioavailability similar to that of a liquid GHB dosage form.

The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed / controlled release components of gamma-hydroxybutyric acid.

The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

The present invention is directed to the treatment of addiction, and particularly to addictions with a chemical dependency component, with gamma-hydroxybutyrate (GHB) and at least one gamma-aminobutyric acid (B) receptor agonist (GABAB receptor agonist), for example, baclofen. Pharmaceutical compositions therefor are also provided.

The invention discloses a 400 V electrolytic capacitor and a production technology thereof. The 400 V electrolytic capacitor comprises a shell, a core, a sealing plug, a negative wire and a positive wire, wherein the core comprises a cathode foil and an anode foil; the core further comprises insulating electrolytic paper; electrolyte is added to the insulating electrolytic paper; the electrolyte is composed of ethylene glycol accounting for 40%-50%, diethylene glycol accounting for 10%-20%, triethylene glycol accounting for 10%-20%, glycerol accounting for 10%-20%, gamma-hydroxybutyrate lactone accounting for 10%-20%, sebacic acid accounting for 1%-10%, ammonium sebacate accounting for 1%-10%, o-nitroanisole accounting for 0.1%-0.9%, p-nitrobenzyl alcohol accounting for 0.1%-0.9%, benzene accounting for 0.1%-1%, polyvinyl alcohol accounting for 0.1%-1% and citric acid accounting for 0%-0.5%. The electrolytic capacitor has good temperature tolerance and long service life, and the load life reaches to 10000-15000 hours at 105 DEG C.

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

The present application relates to compositions for use in a method of treating and / or preventing mental and behavioral disorders and / or improving mental health and cognitive functions in a subject, comprising:a) Docosahexaenoic acid (DHA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;b) Eicosapentaenoic acid (EPA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;c) γ-linolenic acid (GLA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof; andat least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and / or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.The present application also relates to the method of treating and / or preventing mental and behavioral disorders and / or improving mental health and cognitive functions in a subject, comprising administering an effective amount of a composition comprising:a) Docosahexaenoic acid (DHA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;b) Eicosapentaenoic acid (EPA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof;c) γ-linolenic acid (GLA) and / or the pharmaceutically acceptable derivatives and / or precursors thereof; andat least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and / or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.

The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

The invention discloses a 100V electrolytic capacitor and a producing process thereof, wherein the capacitor comprises a shell, a core, a seal plug, a cathode lead and an anode lead; the core comprises a cathode foil and an anode foil and also comprises insulation electrolytic paper; components of electrolyte added to the insulation electrolytic paper comprise 40-70% of ethylene glycol, 10-40% of glycerin, 10-40% of gamma-hydroxybutyrate lactone, 1-10% of ammonium benzoate, 1-10% of azelaic acid EG (ethylene glycol) solution, 2-8% of ammonium hydrogen maleate, 0.1-0.9% of ortho-nitroanisole, 0-0.5% of citric acid, 0.1-0.5% of phosphotungstic acid and 0-0.1% of molybdic acid. The electrolytic capacitor is good in temperature resistance and long in service life, and achieves the load life of 10,000-15,000 hours under the condition of 105 DEG C.